4 papers in the library · 30 citations · publishing 2023-2026
The British Journal of Psychiatry February 10, 2026 Tor-Morten Kvam, Ivar W Goksøyr, Justyna Rog et al.
An abstract is not available for this content. As you have access to this content, full HTML content is provided on this page. A PDF of this content is also available in through the ‘Save PDF’ action button.
The British Journal of Psychiatry July 11, 2025 Tor-Morten Kvam, Ivar W Goksøyr, Justyna Rog et al. 6 citations
3,4-methylenedioxymethamphetamine (MDMA)-assisted therapy (MDMA-AT) has shown promising safety and efficacy in phase 3 studies of post-traumatic stress disorder, but has not been investigated for a primary diagnosis of major depressive disorder (MDD). We aimed to explore the proof of principle and safety as a first study with MDMA-AT for MDD, and to provide preliminary efficacy data. Twelve...
Journal of Eating Disorders June 10, 2025 Camilla Lindvall Dahlgren, Elisabeth Tverrli, Lowan Han Stewart 3 citations
Ketamine, an N-methyl-D-aspartate receptor antagonist, has demonstrated rapid antidepressant effects at sub-anesthetic doses, making it a promising candidate for treatment-resistant mood disorders, anxiety, post-traumatic stress disorder, suicidality, and recently, eating disorders (EDs). However, its effects are transient, and ketamine-assisted psychotherapy (KAP) has emerged as a method to...
Frontiers in Psychiatry November 13, 2023 Tor-Morten Kvam, Malin V. Uthaug, Kristoffer A A Andersen et al. 21 citations
Objective In recent years, there has been a renewed interest in investigating the use of classic psychedelics such as psilocybin and lysergic acid diethylamide (LSD) in the treatment of mental disorders and substance use disorders. However, knowledge about the epidemiology of classic psychedelics in the Nordic countries is limited. Methods We recruited adult, Norwegian participants who have had...